Today: 10 June 2026
Quantum Computing stock whipsaws into Monday after 21% rebound; what to watch next week
8 February 2026
1 min read

Quantum Computing stock whipsaws into Monday after 21% rebound; what to watch next week

NEW YORK, Feb 8, 2026, 09:19 (EST) — The market is closed.

  • Quantum Computing finished Friday’s session at $9.43, notching a 20.7% gain and rebounding from a steep selloff the previous day.
  • Late in the week, risk assets bounced back, with technology stocks out front and bitcoin finding its footing.
  • All eyes are on the next wave of trading volume, with traders also scanning for any new disclosures or filings connected to the company’s recent Luminar Semiconductor agreement.

Shares of Quantum Computing Inc. shot up 20.7% on Friday, finishing at $9.43 and breaking out of a two-day losing streak. Turnover was heavy again, with the stock acting as something of a barometer for risk-taking among retail traders in the quantum space.

The abrupt turn put fresh pressure on near-term positions heading into Monday. Shares tumbled 14.5% Thursday, only to snap back—an up-and-down move that can pull in momentum buyers and squeeze short sellers, provided the rally sticks.

Tech stocks pulled the market higher Friday, part of a bigger “risk-on” move across U.S. markets. Bitcoin also broke back above $70,000. That’s according to a session recap from the Associated Press. AP News

Quantum Computing shares swung from $8.24 to $9.66 on Friday, with some 20.8 million shares traded—about par for the stock’s current turbulent stretch, Yahoo Finance figures show.

Not much in the way of fresh company headlines lately, yet the stock is still under the microscope as investors watch its latest moves. On Feb. 3, a Form 8-K hit the U.S. SEC website, confirming that the Luminar Semiconductor deal wrapped up Feb. 2, with details on cash paid out and escrow arrangements spelled out.

Wall Street analysts remain divided, with most commentary focused on price targets over short-term performance. Earlier this week, MarketBeat highlighted Cantor Fitzgerald’s neutral stance and $15 target, unchanged from its previous note. Over at Ascendiant Capital Markets, the firm still rates the stock a buy, but trimmed its target down to $25 from $40 back in December.

Heading into Monday, traders are eyeing whether Friday’s rebound continues or fizzles right out of the gate. Watch the volume—if it holds up even without new headlines, that might just be noise instead of real buying.

But those rapid-fire gains come with a flipside. Double-digit swings, seen over two straight sessions, leave the stock exposed—any stutter in high-beta tech or even a whiff of dilution from funding chatter can hit prices hard and stretch out those intraday moves.

The company’s next earnings report is the real catalyst to watch, but the timing’s still up in the air. MarketBeat pegs the window around mid-March; MarketScreener says late March. So, no official date yet.

Stock Market Today

  • Is Altria Group (MO) Still a Buy After Recent Share Price Gains?
    June 10, 2026, 8:47 AM EDT. Altria Group (MO) has seen a 30.8% return over the past year, sparking debate on its valuation amid industry shifts. Using a Discounted Cash Flow (DCF) model, Altria is valued at approximately $128.50 per share, suggesting it trades at a 44.3% discount to intrinsic value based on projected future cash flows. This implies the stock is undervalued despite recent gains. Investors weigh factors like the growth of reduced-risk tobacco products, regulatory changes, and capital allocation strategies. Simply Wall St's six-point valuation framework rates Altria 4 out of 6, supporting cautious optimism. The P/E ratio and other valuation metrics are considered to assess if current prices fairly reflect fundamentals. This analysis provides investors a data-backed perspective on Altria's potential upside and risks.

Latest articles

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Shares Fall Again; Microsoft AI Cloud Agreement Still in Focus

10 June 2026
IREN plunged 8.73% to $54.02 Tuesday and slid another 3.72% premarket as investors weighed Wall Street’s bullish calls on its AI cloud buildout against a tech and crypto selloff; the stock’s fate now hinges on IREN’s ability to deliver Microsoft- and Nvidia-linked AI infrastructure on schedule, with the Microsoft contract at risk if timelines slip.
Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Previous Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open
Next Story

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open

Go toTop